These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

798 related items for PubMed ID: 31593702

  • 1. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
    Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, Schoepfer AM, Safroneeva E, Rothenberg ME, Falk GW, Assouline-Dayan Y, Zhao Q, Chen Z, Swanson BN, Pirozzi G, Mannent L, Graham NMH, Akinlade B, Stahl N, Yancopoulos GD, Radin A.
    Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
    [Abstract] [Full Text] [Related]

  • 2. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
    Hirano I, Collins MH, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer AM, Straumann A, Safroneeva E, Grimm M, Smith H, Tompkins CA, Woo A, Peach R, Frohna P, Gujrathi S, Penenberg DN, Li C, Opiteck GJ, Olson A, Aranda R, Rothenberg ME, Dellon ES, HEROES Study Group.
    Gastroenterology; 2019 Feb; 156(3):592-603.e10. PubMed ID: 30395812
    [Abstract] [Full Text] [Related]

  • 3. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age.
    Chehade M, Dellon ES, Spergel JM, Collins MH, Rothenberg ME, Pesek RD, Hirano I, Liu R, Laws E, Mortensen E, Martincova R, Shabbir A, McCann E, Kamal MA, Kosloski MP, Hamilton JD, Samuely C, Lim WK, Wipperman MF, Farrell A, Patel N, Yancopoulos GD, Glotfelty L, Maloney J.
    N Engl J Med; 2024 Jun 27; 390(24):2239-2251. PubMed ID: 38924731
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Rothenberg ME, Dellon ES, Collins MH, Hirano I, Chehade M, Bredenoord AJ, Lucendo AJ, Spergel JM, Sun X, Hamilton JD, Mortensen E, Laws E, Maloney J, Mannent LP, McCann E, Liu X, Glotfelty L, Shabbir A.
    Lancet Gastroenterol Hepatol; 2023 Nov 27; 8(11):990-1004. PubMed ID: 37660704
    [Abstract] [Full Text] [Related]

  • 5. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.
    Dellon ES, Rothenberg ME, Collins MH, Hirano I, Chehade M, Bredenoord AJ, Lucendo AJ, Spergel JM, Aceves S, Sun X, Kosloski MP, Kamal MA, Hamilton JD, Beazley B, McCann E, Patel K, Mannent LP, Laws E, Akinlade B, Amin N, Lim WK, Wipperman MF, Ruddy M, Patel N, Weinreich DR, Yancopoulos GD, Shumel B, Maloney J, Giannelou A, Shabbir A.
    N Engl J Med; 2022 Dec 22; 387(25):2317-2330. PubMed ID: 36546624
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Monoclonal Antibodies for the Treatment of Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    de Oliveira FD, Costa RC, de Santana Sato EDB, Khalil SM, Meine GC.
    Dig Dis Sci; 2024 Jul 22; 69(7):2530-2539. PubMed ID: 38709421
    [Abstract] [Full Text] [Related]

  • 7. Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis.
    Rothenberg ME, Dellon ES, Collins MH, Bredenoord AJ, Hirano I, Peterson KA, Brooks L, Caldwell JM, Fjällbrant H, Grindebacke H, Ho CN, Keith M, McCrae C, Sinibaldi D, White WI, Datto CJ, MESSINA Trial Investigators.
    N Engl J Med; 2024 Jun 27; 390(24):2252-2263. PubMed ID: 38924732
    [Abstract] [Full Text] [Related]

  • 8. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.
    Dellon ES, Katzka DA, Collins MH, Hamdani M, Gupta SK, Hirano I, MP-101-06 Investigators.
    Gastroenterology; 2017 Mar 27; 152(4):776-786.e5. PubMed ID: 27889574
    [Abstract] [Full Text] [Related]

  • 9. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study.
    Bredenoord AJ, Dellon ES, Hirano I, Lucendo AJ, Schlag C, Sun X, Glotfelty L, Mannent L, Maloney J, Laws E, Mortensen E, Shabbir A.
    Gut; 2024 Feb 23; 73(3):398-406. PubMed ID: 38050037
    [Abstract] [Full Text] [Related]

  • 10. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
    Assa'ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, Perschy TL, Jurgensen CH, Ortega HG, Aceves SS.
    Gastroenterology; 2011 Nov 23; 141(5):1593-604. PubMed ID: 21835135
    [Abstract] [Full Text] [Related]

  • 11. Severity of endoscopically identified esophageal rings correlates with reduced esophageal distensibility in eosinophilic esophagitis.
    Chen JW, Pandolfino JE, Lin Z, Ciolino JD, Gonsalves N, Kahrilas PJ, Hirano I.
    Endoscopy; 2016 Sep 23; 48(9):794-801. PubMed ID: 27200524
    [Abstract] [Full Text] [Related]

  • 12. Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results: Analyses From a 12-Week, Phase 2, Randomized, Placebo-controlled Trial.
    Collins MH, Dellon ES, Katzka DA, Hirano I, Williams J, Lan L.
    Am J Surg Pathol; 2019 Nov 23; 43(11):1501-1509. PubMed ID: 31498177
    [Abstract] [Full Text] [Related]

  • 13. Conjunctivitis in dupilumab clinical trials.
    Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A.
    Br J Dermatol; 2019 Sep 23; 181(3):459-473. PubMed ID: 30851191
    [Abstract] [Full Text] [Related]

  • 14. Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis.
    Dellon ES, Collins MH, Rothenberg ME, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer A, Straumann A, Safroneeva E, Rodriguez C, Minton N, Hua SY, Hirano I.
    Clin Gastroenterol Hepatol; 2021 Mar 23; 19(3):473-483.e17. PubMed ID: 32205221
    [Abstract] [Full Text] [Related]

  • 15. Swallowed Fluticasone Propionate Is an Effective Long-Term Maintenance Therapy for Children With Eosinophilic Esophagitis.
    Andreae DA, Hanna MG, Magid MS, Malerba S, Andreae MH, Bagiella E, Chehade M.
    Am J Gastroenterol; 2016 Aug 23; 111(8):1187-97. PubMed ID: 27325220
    [Abstract] [Full Text] [Related]

  • 16. Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension.
    Dellon ES, Collins MH, Katzka DA, Hudgens S, Lan L, Williams J, Vera-Llonch M, Hirano I.
    Clin Gastroenterol Hepatol; 2021 Apr 23; 19(4):699-706.e4. PubMed ID: 32272243
    [Abstract] [Full Text] [Related]

  • 17. Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis.
    Mukkada VA, Gupta SK, Gold BD, Dellon ES, Collins MH, Katzka DA, Falk GW, Williams J, Zhang W, Boules M, Hirano I, Desai NK.
    J Pediatr Gastroenterol Nutr; 2023 Dec 01; 77(6):760-768. PubMed ID: 37718471
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.
    Dellon ES, Woosley JT, Arrington A, McGee SJ, Covington J, Moist SE, Gebhart JH, Tylicki AE, Shoyoye SO, Martin CF, Galanko JA, Baron JA, Shaheen NJ.
    Gastroenterology; 2019 Jul 01; 157(1):65-73.e5. PubMed ID: 30872104
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
    Lucendo AJ, Miehlke S, Schlag C, Vieth M, von Arnim U, Molina-Infante J, Hartmann D, Bredenoord AJ, Ciriza de Los Rios C, Schubert S, Brückner S, Madisch A, Hayat J, Tack J, Attwood S, Mueller R, Greinwald R, Schoepfer A, Straumann A, International EOS-1 Study Group.
    Gastroenterology; 2019 Jul 01; 157(1):74-86.e15. PubMed ID: 30922997
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M.
    Lancet; 2016 Jan 02; 387(10013):40-52. PubMed ID: 26454361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.